Drugs that contain Cilastatin Sodium; Imipenem; Relebactam

1. List of Recarbrio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8487093 MSD MERCK CO β-lactamase inhibitors
Nov, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 16, 2024
Generating Antibiotic Incentives Now (GAIN) Jul 16, 2029

NCE-1 date: July, 2028

Market Authorisation Date: 16 July, 2019

Treatment: Treatment of complicated intra-abdominal infections (ciai); Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp); Treatment of complicated urinary tract infections, including pyelonephritis (cuti)


More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic